These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 31952366)

  • 1.
    Garcia-Carbonero N; Martinez-Useros J; Li W; Orta A; Perez N; Carames C; Hernandez T; Moreno I; Serrano G; Garcia-Foncillas J
    Cells; 2020 Jan; 9(1):. PubMed ID: 31952366
    [No Abstract]   [Full Text] [Related]  

  • 2. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
    Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
    J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
    Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
    Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
    Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
    J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
    World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
    Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
    Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
    J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
    Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
    Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
    Sasaki Y; Hamaguchi T; Yamada Y; Takahashi N; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Nagai Y; Taniguchi H; Boku N; Ushijima T; Shimada Y
    Asian Pac J Cancer Prev; 2016; 17(2):539-43. PubMed ID: 26925640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
    Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
    J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
    Bokemeyer C; Bondarenko I; Hartmann JT; de Braud F; Schuch G; Zubel A; Celik I; Schlichting M; Koralewski P
    Ann Oncol; 2011 Jul; 22(7):1535-1546. PubMed ID: 21228335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanded Low Allele Frequency
    Loree JM; Dowers A; Tu D; Jonker DJ; Edelstein DL; Quinn H; Holtrup F; Price T; Zalcberg JR; Moore MJ; Karapetis CS; O'Callaghan CJ; Waring P; Kennecke HF; Hamilton SR; Kopetz S
    Clin Cancer Res; 2021 Jan; 27(1):52-59. PubMed ID: 33087330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.